Getty
A drug can halve the amount of time that people are laid low by migraines.
Erenumab is an antibody that blocks a brain pathway involving a molecule called CGRP, which becomes more abundant during migraine attacks. In a trial of nearly 1,000 people, the drug was found to typically reduce the number of “migraine days” a person had by three or four days a month.
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
The trial involved taking the drug – or a placebo – for six months. The drug halved the duration of migraines in around half of those who took it.
The study is a step forward for understanding and treating migraine, says Peter Goadsby, from King’s College Hospital, London, who led the trial.
“Migraine can be a debilitating, chronic condition that can destroy lives,” says Simon Evans, of the charity Migraine Action. “We hope this marks the start